Treatment of meningeal malignancy

Oncologist

Volumn 1, Issue 1-2, 1996, Pages 56-61

  Berg, Stagey L ^a,b   Poplack, David G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Brain tumor; Cancer; Cerebrospinal fluid; Chemotherapy; Intrathecal; Meninges; Ommaya

Indexed keywords

EID: 1842423086     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.1-1-56     Document Type: Article

References (19)

1. Bojsen-Moller M, Nielsen J. CNS involvement in leukaemia. ActaPathol Microbiol Immunol Scand [A] 1983;91:209-216.
2. Wolk R, Masse S, Conklin R et al. The incidence of central nervous system leukemia in adults with acute leukemia. Cancer 1974;33:863-869.
3. Posner J, Chernik N. Intracranial metastases from systemic cancer. Adv Neural 1978;19:579-592.
4. Bleyer W. Central nervous system leukemia. Pediatr Clin North Am 1988;35:789-814.
5. Mahmoud H, Rivera G, Hancock M et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993;329:314-319.
6. Mahmoud H, Relling M, Liu Q et al. Presence of leukemic blasts in cerebrospinal fluid is predictive of central nervous system relapse in childhood lymphoblastic leukemia. Proc Am Soc Clin Oncol 1994;13:1048a.
7. Tubergen D, Cullen J, Boyett J et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Children's Cancer Group study. J Clin Oncol 1994;12:272-278.
8. Wasserstrom W, Glass J, Posner J. Diagosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-772.
9. Mulhern R, Kun L. Neuropsychologic function in children with brain tumors. III. Interval changes in the six months following treatment. Med Pediatr Oncol 1985;13:318-324.
10. Pochedly C. Prevention of meningeal leukemia. Review of 20 years of research and current recommendations. Hematol Oncol Clin North Am 1990;4:951-969.
11. Whiteside J, Philips F, Dargeon H et al. Intrathecal amethopterin in neurological manifestations of leukemia. Arch Int Med 1958:101:279-285.
12. Sullivan M, Vietti T, Fernbach D et al. Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate. Blood 1969;34:301-319.
13. Bleyer W. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977;61:1419-1425.
14. Bleyer W, Coccia P, Sather H et al. Reduction in the incidence of central nervous system leukemia with a pharmaco-kinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983;1:317-325.
15. Ochs J. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989;11:93-105.
16. Bleyer W, Drake J, Chabner B. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-773.
17. Price R. Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In: Mastrangelo R, Poplack D, Riccardi R, eds. Central Nervous System Leukemia. Boston: Martinus Nijhoff Publishers, 1983:71-81.
18. Addegio J, Ridgway D, Bleyer W. The acute management of intrathecal methotrexate overdose: pharmacologie rationale and guidelines. J Pediatr 1981;98:825-828.
19. Adamson PC, Balis FM, McCully CL et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991;9:670-674.